Aprea Therapeutics, Inc.APRE

$0.72-0.06 (-8.31%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$5M

Micro-cap

-98%

2019 — today

10-Year Price

-100%

2019 — today

52-Week Range

$0.59$2.08

Current $0.72· 8%

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Valuation in context

P/E ratio

-0.4

N/A

Not meaningful — company is unprofitable

P/B ratio

0.1

Historically cheap

Historically cheap relative to the last 10 years

FCF Yield

-222.3%

Near historic low

Near historic low — last 10 years

Free · No credit card needed

Get alerted when APRE is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.